Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective lifted by JPMorgan Chase & Co. from $32.00 to $36.00 in a research report report published on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other analysts also recently issued reports on the stock. Piper Sandler reaffirmed an overweight rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research note on Tuesday, February 27th. Finally, Oppenheimer reiterated a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $39.33.

Day One Biopharmaceuticals Stock Down 8.7 %

Shares of Day One Biopharmaceuticals stock opened at $15.19 on Monday. The stock has a market cap of $1.33 billion, a PE ratio of -6.38 and a beta of -1.48. The business has a fifty day simple moving average of $15.28 and a 200-day simple moving average of $13.79. Day One Biopharmaceuticals has a 12 month low of $9.67 and a 12 month high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Analysts expect that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the transaction, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeremy Bender sold 7,615 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the sale, the chief executive officer now owns 721,813 shares in the company, valued at $11,007,648.25. The disclosure for this sale can be found here. Insiders have sold 55,781 shares of company stock valued at $883,160 in the last 90 days. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Quest Partners LLC acquired a new stake in Day One Biopharmaceuticals during the 4th quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after purchasing an additional 1,262 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.